Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

Recent executive moves in the industry include new C-suite hires at Editas Medicines, Royalty Pharma and Faron Pharmaceuticals.  

Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.

Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

Emerging Company Profile: BioAge has Phase Ib proof-of-concept data in age-related muscle loss and is gearing up for its first Phase II study, but will need fresh cash or a partner for a potential weight loss-related muscle loss study.

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.

After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.

The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.

CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Recent executive moves in the industry include new C-suite hires at Editas Medicines, Royalty Pharma and Faron Pharmaceuticals.  

China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.

Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.

Financing Snapshot: Seattle biotech claims its targeted, inhalable versions of Esbriet and Ofev, both oral IPF drugs, may offer better tolerability and stronger efficacy than established products.